{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[13,2,13,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910815061603321"]
[null,null,"Titolo",null,"Guidelines for the screening, care and treatment of persons with hepatitis C infection : April 14 / / World Health Organization"]
[null,null,"Pubbl/distr/stampa",null,"Geneva, Switzerland : , : World Health Organization, , [2014]"]
[{"$nulls":4},"©2014"]
[null,null,"ISBN",null,"92-4-069390-4"]
[null,null,"Descrizione fisica",null,"1 online resource (121 p.)"]
[null,null,"Disciplina",null,"616.3623"]
[null,null,"Soggetti",null,"Hepatitis C - Diagnosis"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Cover; CONTENTS; ACKNOWLEDGEMENTS; ABBREVIATIONS AND ACRONYMS; GLOSSARY OF TERMS; EXECUTIVE SUMMARY; 1. SCOPE AND OBJECTIVES; 2. BACKGROUND; 2.1 Epidemiology of hepatitis C; 2.1.1 Routes of transmission; 2.1.2 Coinfections; 2.2 Hepatitis C virus; 2.3 Natural history of HCV infection; 2.4 Prevention of HCV infection; 2.5 Screening for HCV infection; 2.6 Care of patients with HCV infection; 2.7 Treatment of patients with HCV infection; 2.8 Cost-effectiveness of treatment; 3. GUIDING PRINCIPLES; 3.1 Human rights; 3.2 Access to health care; 3.3 Service provision; 3.4 Integrated health care"]
[{"$nulls":4},"4. METHODS5. RECOMMENDATIONS ON SCREENING; 5.1 Screening to identify persons with HCV infection; 5.2 When to confirm a diagnosis of chronic HCV infection; 6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV; 6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake; 6.2 Assessing the degree of liver fibrosis and cirrhosis; 7. RECOMMENDATIONS ON TREATMENT; 7.1 Assessment for HCV treatment; 7.2 Treatment with pegylated interferon and ribavirin; 7.3 Treatment with telaprevir or boceprevir"]
[{"$nulls":4},"7.4 Introduction to recommendations concerning sofosbuvir and simeprevir7.5 Treatment with sofosbuvir; 7.6 Treatment with simeprevir; 8. CLINICAL CONSIDERATIONS; 8.1 Monitoring for toxicity; 8.2 Dose modification; 8.3 Monitoring for efficacy; 9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS; 9.1 People who inject drugs; 9.2 Persons with HIV and HCV coinfection; 9.3 Children and adolescents; 9.4 Persons with liver cirrhosis; 9.5 Persons with HBV and TB coinfection; 9.6 Persons with renal impairment; 10. OPERATIONAL "]
[{"$nulls":4},"AND IMPLEMENTATION ISSUES; 10.1 Service planning; 10.2 Service delivery"]
[{"$nulls":4},"10.3 Future considerations10.4 Dissemination, monitoring and implementation of the Guidelines; 11. REFERENCES"]
[null,null,null,"Sommario/riassunto","These are the first WHO guidelines on the screening  care and treatment ofpersons with HCV infection. They are intended to complement existing guidanceon the primary prevention of HCV and other bloodborne viruses by improvingblood and injection safety  and health care for people who inject drugs (PWID)and other vulnerable groups  including those living with HIV (see section 2.4 forrelated WHO guidelines).These guidelines are primarily targeted at policy-makers in ministries of healthworking in low- and middle-income countries who formulate country-specifictreatment guidelines and who plan infe"]